Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant

Br J Haematol. 2022 Mar;196(5):e38-e40. doi: 10.1111/bjh.17911. Epub 2021 Oct 20.
No abstract available

Keywords: BNT162b2; allogeneic haematopoietic stem cell transplantation; coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA; third dose; vaccine.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Allografts
  • Antibodies, Viral / immunology
  • Antibody Formation
  • BNT162 Vaccine / administration & dosage
  • BNT162 Vaccine / therapeutic use*
  • COVID-19 / immunology
  • COVID-19 / prevention & control*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Organ Transplantation
  • Retrospective Studies
  • SARS-CoV-2 / immunology
  • Stem Cell Transplantation
  • Transplantation, Homologous
  • Young Adult

Substances

  • Antibodies, Viral
  • BNT162 Vaccine